Wiley Matthew T. bought DFTX
September 14, 2026 · Form 4 insider transaction
Wiley Matthew T. bought 125,000 shares of Definium Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
125,000
Price
$0.00
Total value
N/A
InsiderWiley Matthew T.
RoleOfficer
SecurityCommon Shares
Transaction codeA: Grant or award
Transaction dateSeptember 14, 2026
Filing dateSeptember 14, 2026
Shares owned after362,133
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.